European Journal of Clinical Pharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs
ConclusionsOur meta-analysis confirmed the benefits of SGLT2is against 6 kinds of noninfectious respiratory diseases (e.g., Asthma, COPD, and Respiratory failure) and 4 kinds of infectious respiratory diseases (e.g., Bronchitis, and Pneumonia). These findings suggest a likelihood that SGLT2is might be used to prevent or treat these respiratory diseases. Moreover, our meta-analysis for the first time revealed no association between use of SGLT2is and incidence of various site-specific fractures. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 25, 2024 Category: Drugs & Pharmacology Source Type: research

Patterns of inappropriate prescribing and clinical characteristics in patients at admission to an acute care of the elderly unit
ConclusionsWe found statistically significant association between patterns of inappropriate prescribing and clinical and CGA variables such as comorbidity, dependency, dementia or frailty. There is a statistically significant association between patterns of overprescribing among patients admitted to the ACE unit. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 24, 2024 Category: Drugs & Pharmacology Source Type: research

Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study
ConclusionOur findings suggest a protective effect of ACE inhibitors/ARBs against all-cause and cardiovascular mortality, statins against cardiovascular mortality, and CRNMB in patients with AF. Accordingly, these medications should be encouraged in patients with AF when indicated. Additionally, future research should explore whether these medications should be offered to AF patients more routinely. The study was registered with Clinicaltrials.gov (unique identifier number: NCT03917992, Registration date:14/4/2019). (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 23, 2024 Category: Drugs & Pharmacology Source Type: research

Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials
ConclusionAs per the results of our analyses, propofol demonstrated comparatively superior efficacy, however, remimazolam demonstrated comparatively superior safety. The debatable evidence generated from this meta-analysis may not currently be powerful enough to advocate for the use of remimazolam in elderly patients undergoing gastrointestinal procedures; hence, further comprehensive studies are necessary in order to arrive at a robust conclusion. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 23, 2024 Category: Drugs & Pharmacology Source Type: research

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
ConclusionA loading dose plus 3-h maintenance infusions of aztreonam-avibactam in a 3:1 fixed ratio q6h optimizes joint PTA. These analyses supported dose selection for the aztreonam-avibactam Phase III clinical program.Clinical trial registration: NCT01689207; NCT02655419; NCT03329092; NCT03580044. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 22, 2024 Category: Drugs & Pharmacology Source Type: research

A comparison of the mixed and sequential use of acetaminophen and dexketoprofen in painful vaso-occlusive crises
ConclusionOur study suggests that administering acetaminophen and dexketoprofen in the mix for the treatment of painful VOC in patients with SCD may be a more efficient approach compared to sequential administration. This approach appears to reduce opioid usage and shorten hospital stays. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 21, 2024 Category: Drugs & Pharmacology Source Type: research

The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer
ConclusionThere are few head-to-head studies comparing treatments for NSCLC; there are no such studies between the latest generation of drugs. Consequently, ambiguous areas exist due to the lack of comparative studies among the available evidence, preventing the clinician ’s choice of the most effective treatment and risking the patient receiving suboptimal therapy. Simultaneously, the price of the drug cannot be determined correctly, relying only on indirect evaluations from different trials. To dispel this uncertainty, it would be desirable to initiate a process that brings together the demands derived from clinical pr...
Source: European Journal of Clinical Pharmacology - January 20, 2024 Category: Drugs & Pharmacology Source Type: research

Tofacitinib for the treatment of severe rare skin diseases: a narrative review
ConclusionWe explored the mechanism of action, efficacy, and safety considerations of tofacitinib and found that it can be used as a treatment option for rare skin diseases. However, multicenter clinical studies are needed to confirm the efficacy and safety of JAK inhibitors. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 17, 2024 Category: Drugs & Pharmacology Source Type: research